Comment by therein
2 months ago
I like how they aren't saying Semaglutide in the title in an attempt to perhaps keep it from immediate scrutiny.
2 months ago
I like how they aren't saying Semaglutide in the title in an attempt to perhaps keep it from immediate scrutiny.
The first link goes to the study and it does mention the ingredient: https://www.sciencedirect.com/science/article/pii/S2452302X2...
I am talking about UAlberta's title specifically.
"Semaglutide Reduces Cardiomyocyte Size and Cardiac Mass in Lean and Obese Mice" was also written by UoA researchers. I don't see anything nefarious in the choice of the title for the news blurb.
More likely because the average reader won't know what that is versus the current title which succinctly summarizes it.
https://www.fda.gov/drugs/postmarket-drug-safety-information... Same thing??
No. That’s talking about the compounded versions (NOT in an auto pen) that were temporarily allowed due to shortages, but whose authorization has since been revoked.
> Unapproved GLP-1 Drugs Used for Weight Loss Yeah that would be perfect. But editorializing it to the point of calling it `weight loss drug`, just feels like it is begging for the reaction of "oh yet another weight loss drug".